A Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
Diseases and Conditions Researched
Bladder; Breast - Female; Colon; Esophagus; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Lung; Melanoma, skin; Multiple Myeloma; Non-Hodgkin's Lymphoma; Other Digestive Organ; Pancreas; Rectum; Soft Tissue; Stomach; Thyroid
What is the purpose of this trial?
- To evaluate the safety and tolerability of MPDL3280A administered by intravenous (IV) infusion every 3 weeks (q3w) to patients with locally advanced or metastatic solid tumors
- To determine the maximum tolerated dose (MTD) and to evaluate the dose-limiting toxicities (DLTs) of MPDL3280A when administered as a single agent to patients by IV infusion q3w
- To identify a recommended Phase II dose of MPDL3280A
Click here for detailed participation information for this trial.
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.